Corbus Pharmaceuticals Advances Oncology Portfolio with Promising Developments
Corbus Pharmaceuticals Holdings, Inc. a precision oncology company, has recently provided a comprehensive update on the progress of its development of treatments for solid tumors. The company’s Chief Executive Officer, Yuval Cohen, Ph.D., remarked on the significant productivity of the third quarter, highlighting advancements in the company’s three main programs.
The company is preparing to share early clinical experiences with its next-generation Nectin-4 targeting antibody-drug conjugate (ADC), CRB-701, in early 2024. This innovative ADC is engineered to offer a stable ADC with significantly less free-circulating MMAE, which is expected to enhance the therapeutic index compared to existing treatments. The preclinical data, which showed marked differentiation from PADCEV, was presented at the AACR triple meeting in October.
Additionally, the company’s αvβ8 monoclonal antibody, CRB-601, is on track for a USEU Study IND Submission in the fourth quarter of 2023. CRB-601 is designed to inhibit latent TGFb by targeting the integrin avb8. This development was shared at the Society for Immunotherapy of Cancer meeting. Corbus also presented comprehensive data on CRB-913, a peripherally restricted CB1 inverse agonist, which has demonstrated activity both as a monotherapy and in combination with drugs targeting the incretin pathway. A notable aspect of CRB-913 is that it did not result in the loss of lean muscle mass, a significant finding that was presented at Obesity Week.
The Phase 1 clinical trial for CRB-701 is currently recruiting for dose level 6 in China, and early clinical experience is anticipated to be shared in the first quarter of 2024. This will align with the initiation of a trial in the US and EU. The Nectin-4 ADC PADCEV is approved for use in late metastatic urothelial cancer, and CRB-701 will be explored in urothelial cancer among other solid tumors. The preclinical safety profile of CRB-701 supports dosing at higher ADC exposures compared to enfortumab vedotin (PADCEV).
In a recent “Meet the Expert” webinar, Corbus featured several notable oncology experts, including Daniel P. Petrylak, MD (Genitourinary, Yale School of Medicine), Ari Rosenberg, MD (Head and Neck, University of Chicago), and Alexander Spira, MD, Ph.D., FACP (Director of the Virginia Cancer Specialists Research Institute and Co-Director of the Phase 1 Trial Program). These experts discussed the potential of CRB-701 and its differentiating features, such as site-specific conjugation chemistry, a stable linker that leads to low payload release, and a novel Nectin-4 targeting monoclonal antibody with improved speed of internalization.
Corbus Pharmaceuticals has made significant strides in advancing its oncology portfolio. The company’s dedication to developing innovative treatments for solid tumors is evident in the progress of its clinical and preclinical programs. With a focus on improving therapeutic outcomes and addressing unmet medical needs, Corbus continues to contribute valuable research and development in the field of precision oncology. The scientific community and healthcare professionals await further developments with anticipation as Corbus moves closer to potentially providing new options for patients with solid tumors.
Source link
